Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm BaP trial in myeloid and lymphoid cancers
2011-001955-35Phase 2Terminated
- Sponsor
- University of Birmingham
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bezafibrate and medroxyprogesterone acetate in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 1 more, sponsored by University of Birmingham. Primary endpoint: Safety. Started Nov 2011; status: terminated.
02
Drugs
bezafibratemedroxyprogesterone acetate
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2011-001955-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001955-35.